cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.qqveqa
title: Occurrence Download

description: A dataset containing 10968 species occurrences available in GBIF matching the query:
{
 "and" : [
 "DatasetKey is EOD – eBird Observation Dataset",
 "GadmGid is IND",
 "OccurrenceStatus is Present",
 "RecordedBy is obsr433118"
 ]
}

 The dataset includes 10968 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0071048-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30824076
title: Enhanced strength-ductility and stress-rupture properties of a Ni-based superalloy via nanotwins and stable γ’ particles

description: Here, we alter the alloying elements of GH4742 superalloy by means of domain-knowledge informed thermodynamic calculation to reduce the stacking fault energy of the γ matrix and enhance the stability of γ’ particles. Increasing Co and Cr concentrations with Mo substitution by W induces the formation of high-density stacking faults and nanotwins, while reducing the coarsening rate of γ’ particles during tensile testing at 760°C and stress-rupture loading at 760°C/480 MPa. Thus, the yield strength, working-hardening capacity, and stress-rupture life are simultaneously improved, achieving the synergic enhancements in strengths-ductility and stress-rupture properties at elevated temperature.
DOI: 10.6084/m9.figshare.30824076.v1
title: Enhanced strength-ductility and stress-rupture properties of a Ni-based superalloy via nanotwins and stable γ’ particles

description: Here, we alter the alloying elements of GH4742 superalloy by means of domain-knowledge informed thermodynamic calculation to reduce the stacking fault energy of the γ matrix and enhance the stability of γ’ particles. Increasing Co and Cr concentrations with Mo substitution by W induces the formation of high-density stacking faults and nanotwins, while reducing the coarsening rate of γ’ particles during tensile testing at 760°C and stress-rupture loading at 760°C/480 MPa. Thus, the yield strength, working-hardening capacity, and stress-rupture life are simultaneously improved, achieving the synergic enhancements in strengths-ductility and stress-rupture properties at elevated temperature.
DOI: 10.6084/m9.figshare.30484882
title: A Ti-Zr-Hf-Ni-Nb high-entropy shape memory alloy with an exceptional strength-ductility synergy for high-temperature application

description: A novel Ti<sub>35.16</sub>Zr<sub>5.86</sub>Hf<sub>5.86</sub>Ni<sub>46.87</sub>Nb<sub>6.25</sub> (at. %) high-entropy shape memory alloy (HESMA) is developed for applications in high-stress, high-temperature environments. This alloy consists of B19’ martensitic laths with minor β-Nb and Ti<sub>2</sub>Ni particles along grain boundaries. It demonstrates an exceptional strength-ductility synergy, a relatively-high martensitic transformation start temperature (<i>M</i><sub>s</sub> = 392 K), and outstanding shape memory property with maximum recoverable strain (<i>ϵ</i><sub>mre</sub> = 1.94%) under 550 MPa. This combination of characteristics successfully overcomes the traditional trade-off among <i>M</i><sub>s</sub>, strength-ductility, and shape memory effect. Moreover, the thermal-induced transformation behavior is systematically investigated. This work establishes a paradigm for developing high-performance high-temperature HESMAs.
DOI: 10.6084/m9.figshare.30484882.v1
title: A Ti-Zr-Hf-Ni-Nb high-entropy shape memory alloy with an exceptional strength-ductility synergy for high-temperature application

description: A novel Ti<sub>35.16</sub>Zr<sub>5.86</sub>Hf<sub>5.86</sub>Ni<sub>46.87</sub>Nb<sub>6.25</sub> (at. %) high-entropy shape memory alloy (HESMA) is developed for applications in high-stress, high-temperature environments. This alloy consists of B19’ martensitic laths with minor β-Nb and Ti<sub>2</sub>Ni particles along grain boundaries. It demonstrates an exceptional strength-ductility synergy, a relatively-high martensitic transformation start temperature (<i>M</i><sub>s</sub> = 392 K), and outstanding shape memory property with maximum recoverable strain (<i>ϵ</i><sub>mre</sub> = 1.94%) under 550 MPa. This combination of characteristics successfully overcomes the traditional trade-off among <i>M</i><sub>s</sub>, strength-ductility, and shape memory effect. Moreover, the thermal-induced transformation behavior is systematically investigated. This work establishes a paradigm for developing high-performance high-temperature HESMAs.
DOI: 10.13140/rg.2.2.19806.91200
title: Documenting the Knowledge, Skills and Practices of the Last Remaining Sign Painters in Ho Chi Minh City - Guide to the Dataset
DOI: 10.6084/m9.figshare.30508555
title: Microstructural heterogeneity enabled balance of room- and high-temperature properties in high-volume intermetallics reinforced aluminum alloys

description: Incorporating high-volume-fraction intermetallics into aluminum alloys is a typical way to enhance both room- and high-temperature strength, yet often sacrifices ductility. In this study, a novel Al–Si–Fe–Ni–Mn alloy with 35.6 vol.% and multi-scale heterogeneous IMCs was fabricated via powder metallurgy and thermo-mechanical processing. The alloy achieves an exceptional balance of room-temperature strength (477 MPa), ductility (8.2%) and high-temperature strength (277 MPa at 300°C), demonstrating remarkable strength-ductility synergy and superior heat resistance. This arises from a hierarchical architecture that coordinates deformation across multiple size scales. The findings presented herein provide fresh perspectives for the design of high-performance aluminum alloys. A high-volume-fraction, multi-scale IMCs-strengthened aluminum alloy with a heterogeneous microstructure is designed and investigated, achieving significantly enhanced room-temperature and high-temperature (exceeding 300°C) mechanical properties.
DOI: 10.6084/m9.figshare.30508555.v1
title: Microstructural heterogeneity enabled balance of room- and high-temperature properties in high-volume intermetallics reinforced aluminum alloys

description: Incorporating high-volume-fraction intermetallics into aluminum alloys is a typical way to enhance both room- and high-temperature strength, yet often sacrifices ductility. In this study, a novel Al–Si–Fe–Ni–Mn alloy with 35.6 vol.% and multi-scale heterogeneous IMCs was fabricated via powder metallurgy and thermo-mechanical processing. The alloy achieves an exceptional balance of room-temperature strength (477 MPa), ductility (8.2%) and high-temperature strength (277 MPa at 300°C), demonstrating remarkable strength-ductility synergy and superior heat resistance. This arises from a hierarchical architecture that coordinates deformation across multiple size scales. The findings presented herein provide fresh perspectives for the design of high-performance aluminum alloys. A high-volume-fraction, multi-scale IMCs-strengthened aluminum alloy with a heterogeneous microstructure is designed and investigated, achieving significantly enhanced room-temperature and high-temperature (exceeding 300°C) mechanical properties.
DOI: 10.6084/m9.figshare.27302021
title: Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System

description: Carbamazepine (CBZ) is a commonly used antiseizures medications (ASM), but its adverse drug reactions (ADRs) can impact the successful management of epilepsy. There are currently limited systematic studies on ADRs related to CBZ, necessitating further investigation. Using the FDA Adverse Event Reporting System (FAERS) database , we extracted reports where CBZ was the primary suspect, conducting subgroup analyses stratified by sex and age. Four risk signal detection methods ROR, PRR, BCPNN, and EGBM were employed to systematically analyze the ADRs associated with CBZ. In the epilepsy population, ADRs related to CBZ often involve examinations, hereditary disorders, and infections. Subgroup analysis showed differences in ADR signals among male, female, elderly, and young patients. Human Herpesvirus 6 Infection and Dermatitis Exfoliative were consistent CBZ-induced ADRs, unaffected by age or sex. The study also identified previously overlooked ADRs such as bone metabolism abnormalities, ocular toxicity, and ototoxicity. Many ADRs linked to CBZ remain underreported. It is crucial to enhance monitoring and information dissemination about CBZ use in epileptic patients. Adjusting medication regimens for high-risk individuals, potentially incorporating acupuncture, traditional Chinese medicine, or alternative anti-seizure medications, should be considered when necessary.
DOI: 10.6084/m9.figshare.27302021.v2
title: Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System

description: Carbamazepine (CBZ) is a commonly used antiseizures medications (ASM), but its adverse drug reactions (ADRs) can impact the successful management of epilepsy. There are currently limited systematic studies on ADRs related to CBZ, necessitating further investigation. Using the FDA Adverse Event Reporting System (FAERS) database , we extracted reports where CBZ was the primary suspect, conducting subgroup analyses stratified by sex and age. Four risk signal detection methods ROR, PRR, BCPNN, and EGBM were employed to systematically analyze the ADRs associated with CBZ. In the epilepsy population, ADRs related to CBZ often involve examinations, hereditary disorders, and infections. Subgroup analysis showed differences in ADR signals among male, female, elderly, and young patients. Human Herpesvirus 6 Infection and Dermatitis Exfoliative were consistent CBZ-induced ADRs, unaffected by age or sex. The study also identified previously overlooked ADRs such as bone metabolism abnormalities, ocular toxicity, and ototoxicity. Many ADRs linked to CBZ remain underreported. It is crucial to enhance monitoring and information dissemination about CBZ use in epileptic patients. Adjusting medication regimens for high-risk individuals, potentially incorporating acupuncture, traditional Chinese medicine, or alternative anti-seizure medications, should be considered when necessary.
DOI: 10.6084/m9.figshare.27153749
title: Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study

description: The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs. The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use. Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.
DOI: 10.6084/m9.figshare.27204728
title: RETRACTED ARTICLE: Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS)

description: RETRACTED ARTICLE: Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS)
DOI: 10.6084/m9.figshare.27204728.v2
title: Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS)

description: Letairis (ambrisentan), an endothelin receptor antagonist (ERA), is a critical medication for pulmonary arterial hypertension (PAH). Despite its efficacy, its safety profile is under scrutiny, warranting a detailed analysis. This study leveraged the FDA Adverse Event Reporting System (FAERS) from Q1 2007 to Q4 2023, focusing on Letairis as the primary suspect in adverse events. Employing advanced data mining techniques, such as Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS), the study aimed to uncover safety signals. A total of 43,774 cases were identified, with Letairis implicated in 16,038,963 adverse event reports. There was a notable predominance of female patients (75.30%), with a median age around 64 years. Severe outcomes, including hospitalization (51.63%) and fatalities (20.44%), were prevalent. Signal strength analysis highlighted concerns in infections and infestations, as well as cardiac disorders. The analysis underscores the need for vigilant pharmacovigilance and highlights Letairis’s potential to induce serious AEs, particularly in female and elderly populations. These findings are instrumental in guiding clinical practice and future drug safety assessments.
DOI: 10.6084/m9.figshare.27204728.v3
title: RETRACTED ARTICLE: Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS)

description: RETRACTED ARTICLE: Clinical adverse events to letairis: a real-world drug safety study based on FDA Adverse Event Reporting System (FAERS)
DOI: 10.6084/m9.figshare.27302021.v1
title: Adverse events associated with carbamazepine: a pharmacovigilance study using the FDA Adverse Event Reporting System

description: Carbamazepine (CBZ) is a commonly used antiseizures medications (ASM), but its adverse drug reactions (ADRs) can impact the successful management of epilepsy. There are currently limited systematic studies on ADRs related to CBZ, necessitating further investigation. Using the FDA Adverse Event Reporting System (FAERS) database , we extracted reports where CBZ was the primary suspect, conducting subgroup analyses stratified by sex and age. Four risk signal detection methods ROR, PRR, BCPNN, and EGBM were employed to systematically analyze the ADRs associated with CBZ. In the epilepsy population, ADRs related to CBZ often involve examinations, hereditary disorders, and infections. Subgroup analysis showed differences in ADR signals among male, female, elderly, and young patients. Human Herpesvirus 6 Infection and Dermatitis Exfoliative were consistent CBZ-induced ADRs, unaffected by age or sex. The study also identified previously overlooked ADRs such as bone metabolism abnormalities, ocular toxicity, and ototoxicity. Many ADRs linked to CBZ remain underreported. It is crucial to enhance monitoring and information dissemination about CBZ use in epileptic patients. Adjusting medication regimens for high-risk individuals, potentially incorporating acupuncture, traditional Chinese medicine, or alternative anti-seizure medications, should be considered when necessary.
DOI: 10.6084/m9.figshare.27153749.v1
title: Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study

description: The sodium-dependent glucose transporters 2 inhibitors (SGLT-2i) is associated with body weight loss but the composition of the losing weight remains unclear. Disproportionality analyses, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi- item gamma Poisson shrinker (MGPS) algorithms, were employed to quantify the signals of SGLT-2i-associated musculoskeletal and connective tissue disorders AEs. The search retrieved a total of 3,206 cases of musculoskeletal and connective tissue disorder-related AEs during the reporting period. This included 1,061 cases for Canagliflozin, 1,052 cases for Dapagliflozin, 1,074 cases for Empagliflozin, and 19 cases for Ertugliflozin. Fifteen preferred terms (PTs) with significant disproportionality were retained. No musculoskeletal and connective tissue system-related AE signals were reported for Ertugliflozin. We identified a risk of muscle necrosis with Canagliflozin use, a risk of sarcopenia with Dapagliflozin use, and a chance of muscle atrophy with Dapagliflozin and Empagliflozin prescriptions. Most cases occurred within the first month after SGLT-2i initiation, and AEs can persist beyond 360 days of use. Our study identified potential new musculoskeletal and connective tissue disorder-related AE signals associated with SGLT-2 inhibitors.
DOI: 10.6084/m9.figshare.30987604
title: Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study

description: Recombinant human erythropoietin (rhEPO) fused with human immunoglobulin G (IgG) Fc fragment (rhEPO-Fc) is a novel erythropoiesis-stimulating agent designed to extend plasma half-life and enhance biological activity. However, data on the efficacy and safety of rhEPO-Fc in hemodialysis patients with chronic kidney disease (CKD)-related anemia remain limited. This phase 3 trial enrolled patients from 45 Chinese hospitals. Participants were randomized (2:1) to receive either rhEPO-Fc or rhEPO (Chinese hamster ovary cell-derived) for 28 weeks. The rhEPO-Fc responders were eligible for a 24-week extension period. The primary endpoint was the least square mean (LSM) change in hemoglobin (Hb) levels from baseline between weeks 21 and 28. Among 356 rhEPO-Fc and 178 rhEPO recipients, patients receiving rhEPO-Fc demonstrated non-inferiority Hb maintenance compared with rhEPO. The inter-group LSM differences in the full analysis set and per-protocol set were 3.96 g/L (95% CI: 3.02–4.89; <i>p</i> &lt; 0.001) and 2.27 g/L (95% CI: 0.60–3.95; <i>p</i> = 0.008), respectively. Adverse drug reaction rates were comparable (rhEPO-Fc: 39.2% vs. rhEPO: 40.2%). Dose adjustments due to treatment-emergent adverse events were significantly lower with rhEPO-Fc (0.0% vs. 2.2%; <i>p</i> &lt; 0.05). Deaths unrelated to the study drugs occurred in two rhEPO-Fc and four rhEPO patients. These findings indicated that rhEPO-Fc effectively maintained Hb levels in patients with CKD anemia undergoing hemodialysis, showing comparable efficacy to rhEPO with reduced dosing frequency and a similar safety profile.
DOI: 10.6084/m9.figshare.30987604.v1
title: Effects of rhEPO-Fc on chronic renal anemia in Chinese patients undergoing maintenance hemodialysis: a multicenter, randomized, open-label, and phase 3 study

description: Recombinant human erythropoietin (rhEPO) fused with human immunoglobulin G (IgG) Fc fragment (rhEPO-Fc) is a novel erythropoiesis-stimulating agent designed to extend plasma half-life and enhance biological activity. However, data on the efficacy and safety of rhEPO-Fc in hemodialysis patients with chronic kidney disease (CKD)-related anemia remain limited. This phase 3 trial enrolled patients from 45 Chinese hospitals. Participants were randomized (2:1) to receive either rhEPO-Fc or rhEPO (Chinese hamster ovary cell-derived) for 28 weeks. The rhEPO-Fc responders were eligible for a 24-week extension period. The primary endpoint was the least square mean (LSM) change in hemoglobin (Hb) levels from baseline between weeks 21 and 28. Among 356 rhEPO-Fc and 178 rhEPO recipients, patients receiving rhEPO-Fc demonstrated non-inferiority Hb maintenance compared with rhEPO. The inter-group LSM differences in the full analysis set and per-protocol set were 3.96 g/L (95% CI: 3.02–4.89; <i>p</i> &lt; 0.001) and 2.27 g/L (95% CI: 0.60–3.95; <i>p</i> = 0.008), respectively. Adverse drug reaction rates were comparable (rhEPO-Fc: 39.2% vs. rhEPO: 40.2%). Dose adjustments due to treatment-emergent adverse events were significantly lower with rhEPO-Fc (0.0% vs. 2.2%; <i>p</i> &lt; 0.05). Deaths unrelated to the study drugs occurred in two rhEPO-Fc and four rhEPO patients. These findings indicated that rhEPO-Fc effectively maintained Hb levels in patients with CKD anemia undergoing hemodialysis, showing comparable efficacy to rhEPO with reduced dosing frequency and a similar safety profile.
DOI: 10.3886/e242234v1
title: Federal University of Agriculture, Zuru 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Federal University of Agriculture, Zuru 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242232v1
title: Nigerian Army University, Biu 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Nigerian Army University, Biu 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242241v1
title: African Aviation and Aerospace University 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: African Aviation and Aerospace University 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242240v1
title: Admiralty University Ibusa 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Admiralty University Ibusa 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242239v1
title: David Nweze Umahi Federal University of Medical Sciences, Uburu 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: David Nweze Umahi Federal University of Medical Sciences, Uburu 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242238v1
title: Federal University of Health Sciences, Ila Orangun 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Federal University of Health Sciences, Ila Orangun 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242237v1
title: Federal University of Health Sciences, Azare 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Federal University of Health Sciences, Azare 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242236v1
title: ederal University of Technology, Ikot Abasi 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: ederal University of Technology, Ikot Abasi 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542
DOI: 10.3886/e242235v1
title: Federal University of Technology, Babura 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542

description: Federal University of Technology, Babura 2026/2027 Pre-Degree Form, Part-time Form Is Out Call 07076040542 To Apply and further admission assistance. Call Prof. Ben +2347076040542